A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Exclusion Criteria

• •nean sitDBP ≥ 116mmHg or mean sitSBP ≥ 200mmHg at Visit 1, Visit 2, Visit 3
• •The change of mean sitDBP ≥ 10mmHg or mean sitSBP ≥ 20mmHg on target arm at Visit 1
• •Known or suspected Stage 2 Hypertension (aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
• •Patients with congestive heart failure(NYHA class III\~IV), ischemic heart disease, cardiomyopathy, heart valve disorder, arrhythmia, coronary artery bypass graft
• •History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
• •Type I Diabets Mellitus, Type II Diabetes Mellitus with HbA1c \> 8%
• •History of severe or malignant retinopathy
• •AST/ALT \> UNL \* 2, Serum Creatinine \> UNL \* 1.5, K \> 5.5mEq/L
• •Patients with acute or chronic inflammatory status, autoimmune disease
• •Patients who need to take antihypertensive drug besides Investigational products
• •Patients must be treated with medications prohibited for concomitant use during study period
• •Hypersensitive to Candesartan/Amlodipine or other dihydropyridine drugs
• •Hereditary angioedema or history of angioedema related to ACE inhibitor or angiotensin II receptor blockers
• •History of malignant tumor within 5 years
• •Patients who are dependent on drugs or alcohol
• •History of disability to drug absorption, active inflammatory bowel syndrome with 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract
• •Patients treated with other investigational product within 4 weeks at the time concents are obtained
• •Women with pregnant, breast-feeding